FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
November 04, 2024 06:00 ET
|
R3 Vascular
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating...
Sonablate announces first patient enrolled in HIFIVE U.S. clinical trial for ablation of incompetent veins
October 28, 2024 14:36 ET
|
Sonablate
HIFIVE is a Phase I trial to assess the safety and performance of Sonablate high-intensity focused ultrasound for treating incompetent veins
[Latest] Global Medical Aesthetics Market Size/Share Worth USD 36,168.8 Million by 2033 at a 8.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
August 06, 2024 03:30 ET
|
Custom Market Insights
Austin, TX, USA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Medical Aesthetics Market Size, Trends and Insights By Product Type (Aesthetic...
R3 Vascular Appoints Josh Smale as its Vice President of Global Clinical and Scientific Affairs
July 09, 2024 14:25 ET
|
R3 Vascular
R3 Vascular Inc. is pleased to announce the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs.
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO
May 09, 2024 12:00 ET
|
R3 Vascular
R3 Vascular, Inc. announced the closing of its $87 million Series B financing round and the appointment of a new President and Chief Executive Officer
Teleflex Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray
May 09, 2024 06:30 ET
|
Teleflex Incorporated
WAYNE, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies and pioneer in intraosseous vascular access, today announced the launch of the...
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
May 08, 2024 09:00 ET
|
Therini Bio, Inc.
THN391, a mAb designed to block neuroinflammation triggered by fibrin, demonstrated effectiveness in protecting against vascular and neuronal degeneration
“I Need to See It With My Own Eyes”: How US Ophthalmologists React to Apellis’ Syfovre Safety Warnings When Managing Geographic Atrophy
December 14, 2023 12:58 ET
|
Spherix Global Insights
Exton, PA, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Geographic Atrophy (GA), the most severe stage of dry age-related macular degeneration (dAMD), poses a significant challenge as retinal cells atrophy,...
Teleflex Awarded Peripheral Access Agreement with Premier, Inc.
December 05, 2023 06:30 ET
|
Teleflex Incorporated
WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing...
Teleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry
November 16, 2023 06:30 ET
|
Teleflex Incorporated
WAYNE, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical...